330 related articles for article (PubMed ID: 24563540)
21. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732
[TBL] [Abstract][Full Text] [Related]
22. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
[TBL] [Abstract][Full Text] [Related]
23. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.
Xu X; Wei WB; Li B; Gao F; Zhang Z; Jonas JB
PLoS One; 2014; 9(10):e109699. PubMed ID: 25280020
[TBL] [Abstract][Full Text] [Related]
25. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
26. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD; McKean M
Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
[TBL] [Abstract][Full Text] [Related]
27. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
[TBL] [Abstract][Full Text] [Related]
28. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
[TBL] [Abstract][Full Text] [Related]
29. Uveal Melanoma:
Psinakis F; Katseli A; Koutsandrea C; Frangia K; Florentin L; Apostolopoulou D; Dimakopoulou K; Papakonstantinou D; Georgopoulou E; Brouzas D
Anticancer Res; 2017 Oct; 37(10):5719-5726. PubMed ID: 28982892
[TBL] [Abstract][Full Text] [Related]
30. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
[TBL] [Abstract][Full Text] [Related]
31. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
[TBL] [Abstract][Full Text] [Related]
32. In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations.
Piaggio F; Croce M; Reggiani F; Monti P; Bernardi C; Ambrosio M; Banelli B; Dogrusöz M; Jockers R; Bordo D; Puzone R; Viaggi S; Coviello D; Lanza FB; Bartolucci M; Petretto A; Mosci C; Gangemi R; van der Velden PA; Jager MJ; Pfeffer U; Amaro A
Eur J Cancer; 2022 Jul; 170():27-41. PubMed ID: 35580369
[TBL] [Abstract][Full Text] [Related]
33. Functional characterization of uveal melanoma oncogenes.
Ma J; Weng L; Bastian BC; Chen X
Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations.
Mudhar HS; Doherty R; Salawu A; Sisley K; Rennie IG
Br J Ophthalmol; 2013 Jul; 97(7):924-8. PubMed ID: 23685997
[TBL] [Abstract][Full Text] [Related]
35. Combined Inhibition of Gα
Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
[TBL] [Abstract][Full Text] [Related]
36. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles.
Posch C; Latorre A; Crosby MB; Celli A; Latorre A; Vujic I; Sanlorenzo M; Green GA; Weier J; Zekhtser M; Ma J; Monico G; Char DH; Jusufbegovic D; Rappersberger K; Somoza Á; Ortiz-Urda S
Biomed Microdevices; 2015 Feb; 17(1):15. PubMed ID: 25653058
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
38. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.
Koopmans AE; Vaarwater J; Paridaens D; Naus NC; Kilic E; de Klein A;
Br J Cancer; 2013 Jul; 109(2):493-6. PubMed ID: 23778528
[TBL] [Abstract][Full Text] [Related]
39. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract][Full Text] [Related]
40. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
